ACADIA Pharmaceuticals Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ACAD Nasdaq 2834 http://www.acadia-pharm.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ACADIA Pharmaceuticals Inc.

Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other Updates - Oct 9th, 2019 3:18 pm
Acadia Sees Strong Results in Dementia Treatment - Oct 8th, 2019 10:00 am
ACADIA Pharmaceuticals Presents Additional Positive Data from the Phase 2 CLARITY Study with Pimavanserin in Adjunctive Major Depressive Disorder at 2019 Psych Congress - Oct 7th, 2019 1:00 pm
ACADIA Pharmaceuticals Announces Late-Breaking Oral Presentation of the Phase 3 HARMONY Study of Pimavanserin in Dementia-Related Psychosis at the Clinical Trials on Alzheimer’s Disease (CTAD) 2019 Meeting - Oct 3rd, 2019 8:55 pm
We Think ACADIA Pharmaceuticals (NASDAQ:ACAD) Can Easily Afford To Drive Business Growth - Oct 2nd, 2019 10:37 am
Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar? - Sep 26th, 2019 1:14 pm
ACADIA Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019 - Sep 25th, 2019 8:05 pm
ACADIA Pharmaceuticals Announces that The Journal of Clinical Psychiatry Publishes Positive Phase 2 CLARITY Results for Pimavanserin as Adjunctive Treatment for Patients with Major Depressive Disorder - Sep 24th, 2019 8:05 pm
ACADIA Pharmaceuticals Presents New Data on PD Patients Treated with Pimavanserin for Depression at the 2019 International Congress of Parkinson’s Disease and Movement Disorders - Sep 23rd, 2019 1:00 pm
ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares - Sep 20th, 2019 8:05 pm
Gilead, AbbVie Are Innovative, but May Be Underappreciated - Sep 20th, 2019 5:10 pm
ACADIA Pharmaceuticals to Present New Clinical Data and Outcomes Research at Upcoming Scientific Meetings - Sep 19th, 2019 1:00 pm
ACADIA Pharmaceuticals Prices Public Offering of Common Stock - Sep 18th, 2019 3:00 am
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock - Sep 17th, 2019 8:02 pm
5 Top Stock Trades for Wednesday: BA, ACB, PINS - Sep 17th, 2019 7:25 pm
3 Hot Biotechs with High Upside Potential - Sep 11th, 2019 2:23 pm
'Pleasantly Surprised' Acadia Analysts See Blockbuster Potential For Pimavanserin In Dementia Psychosis - Sep 10th, 2019 5:20 pm
ACADIA Surges on Early Success of Nuplazid Dementia Study - Sep 10th, 2019 3:41 pm
Will ACADIA Continue to Surge Higher? - Sep 10th, 2019 2:59 pm
Is Acadia Pharmaceuticals a Good Biotech Stock to Buy Now? - Sep 10th, 2019 12:39 pm